health Boehringer Ingelheim Obesity Drug Shows Significant Weight Loss in Phase 3 Trial
Boehringer Ingelheim's investigational obesity therapy, survodutide, achieved up to 16.6% average weight loss in a Phase 3 trial, targeting appetite and liver metabolism.
